Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 9.6a

Immunosuppression Use for Induction, 1998 to 2007

Recipients with Liver Transplants

  Year of Transplant
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 4,516 4,751 4,997 5,195 5,332 5,673 6,170 6,443 6,650 6,489
With Immunosuppression Info 4,199 4,441 4,846 5,032 5,198 5,520 5,972 6,164 6,406 6,207
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 1.2% 0.7% 0.7% 0.4% 0.5% 0.5% 0.4% 0.2% 0.3% 1.2%
OKT3 3.6% 1.4% 0.8% 0.7% 0.3% 0.3% 0.2% 0.8% 2.7% 2.9%
Thymoglobulin 0.1% 0.5% 1.2% 2.4% 4.2% 6.5% 7.4% 7.3% 8.9% 9.6%
Zenapax 2.9% 6.6% 6.6% 5.8% 4.6% 5.6% 4.7% 4.0% 5.8% 8.2%
Simulect 1.4% 4.4% 6.6% 6.2% 7.8% 7.2% 6.4% 7.1% 6.5% 5.6%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 1.6% 1.6% 1.4% 1.4%
No Induction Drugs Recorded 91.0% 86.7% 84.5% 84.6% 82.7% 79.5% 79.5% 79.9% 77.2% 74.2%


Source: OPTN/SRTR Data as of May 1, 2008.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader